# Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Breast Recontruction

> **NCT03393117** · PHASE2 · WITHDRAWN · sponsor: **Case Comprehensive Cancer Center**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Liposomal Bupivacaine
- **DRUG:** Bupivacaine
- **DRUG:** Patient-Controlled Analgesia Pump
- **DRUG:** Oral Narcotic

## Key facts

- **NCT ID:** NCT03393117
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-03-30
- **Primary completion:** 2020-07-01
- **Final completion:** 2020-07-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No accrual
- **Last updated:** 2020-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03393117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03393117, "Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Breast Recontruction". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03393117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*